Many cancers possess elevated levels of PtdIns (3,4,5)P 3 , the second messenger that induces activation of the protein kinases PKB/Akt and S6K and thereby stimulates cell proliferation, growth, and survival [1, 2]. The importance of this pathway in tumorigenesis has been highlighted by the finding that PTEN, the lipid phosphatase that breaks down PtdIns(3,4,5)P 3 to PtdIns(4,5)P 2 , is frequently mutated in human cancer 
promising anticancer target for the prevention of tumors that possess elevated PKB and S6K activity.
Results and Discussion
Generation of PDK1 Hypomorphic PTEN +/− Mice In this study we explore whether suppression of PDK1 expression inhibits tumorigenesis in PTEN +/− mice. As PDK1 −/− mice fail to develop beyond embryonic day (E)9.5 of embryogenesis, we generated hypomorphic PDK1 fl/fl mice in which the neomycin resistance gene is inserted into an intron sequence between exons 2 and 3 of the PDK1 gene in order to interfere with its expression ( Figure 1A ) [15] . The presence of the neomycin gene reduces the expression of PDK1 by 80%-90% in all tissues, and its removal using the CRE recombinase restores normal levels of PDK1 [15] . PDK1 fl/fl mice, as well as PDK1 −/fl mice possessing even lower levels of PDK1, are viable and fertile, and the only marked phenotype is that they are 30%-40% smaller than control littermates [15] .
We crossed the hypomorphic PDK1 −/fl mice with PTEN +/− mice as described in Figure 
Analysis of Tumors
Mice were culled when they exhibited large external tumors, lost weight, became sick or reached 15 months of age. A necroscopy was performed, the tissues fixed in 10% formalin, and subjected to detailed histopathological examination. The types of tumors and the proportion of mice displaying these lesions are summarized in Table 1 Figure 3J ). Other types of tumors including, colon adenoma, thyroid carcinoma, liver hepatoma, and lung adenocarcinoma are also observed but with lower incidence (Table 1 ). In addition to these primary tumors, pulmonary metastases were also seen.
In Some differences in staining between tumor types were however observed. S6 protein was highly phosphorylated in all of the carcinomas but was low in the phaeochromocytomas. In the lymphomas, which were all of follicular origin, the S6 protein phosphorylation was seen in centroblasts, but not in centrocytes. The pattern of FOXO1 cytosolic staining closely matched that seen for phospho-S6 protein. There was strong FOXO1 cytoplasmic staining of the tumor cells of both breast and prostate carcinoma, whereas in lymphoma cytoplasmic staining of centroblasts was detected but with weaker nuclear staining of some centrocytes. We were unable to detect FOXO1 in the phaeochromocytomas. Ki67 staining was observed in w10% of lymphomas (again mostly centroblasts) and w5% of phaeochromocytomas. (Figures 3M and 3N) +/fl PTEN +/− mice that had never been used for breeding displayed persistent trophoblast (Table 1) . In contrast, trophoblast is not normally observed in mice that have not previously bred. Two separate events must have occurred to account for this observation, namely partenogenetic fertilization of an ovum and formation and persistence of trophoblast. Trophoblast development from oocytes is dependent upon expression from the paternal copy of the IGF-2 gene, as the maternal copy of IGF-2 gene is imprinted and not expressed [20] . The signaling pathway by which IGF-2 stimulates trophoblast development is unknown. How- M and N). Haematoxylin and eosin, original  magnification ×120. (A), (C), (D), (F), (H), (J), (K), and (M 
Analysis of Preneoplastic Lesions

PDK1 as an Anticancer Target
Much effort is being devoted to developing anticancer drugs that inhibit components of the PI 3-kinase signaling pathway in order to treat tumors that have mutations in PTEN and other signaling networks that elevate the level of PtdIns(3,4,5)P 3 and/or enhance PKB and S6K activity. The PDK1 hypomorphic mice utilized in this study represent a genetic model that would be ex-pected to mimic PTEN +/− mouse treated with a drug that reduces the endogenous activity of PDK1 by 80%-90%. The finding that a reduction in PDK1 activity by this amount markedly protects and/or delays tumor formation in PTEN +/− mice suggests that PDK1 is a promising anticancer target to prevent the formation of human tumors with elevated PKB and S6K activity.
Our results do not address the question of whether inhibiting PDK1 in an established tumor would prevent its growth or induce regression of the tumor. Recently however, relatively specific, small molecule inhibitors of PDK1 were described, which inhibited the growth and induced apoptosis of a wide range of cancer cell lines as well as suppressing the growth of melanoma tumors in a nude mice model [21] . Another drug with anticancer properties, 7-hydroxystaurosporine (also termed UCN-01), was originally reported to function as a CHK1 inhibitor but subsequently found to inhibit PDK1 with similar potency [22, 23] , suggesting that some of the antitumorigenesis properties of this compound might be mediated through inhibition of PDK1. These findings, together with the genetic studies described in this paper, suggest that PDK1 inhibitors are likely to have utility in both the prevention and treatment of cancers that have elevated PtdIns(3,4,5)P 3 levels and/or PKB and S6K activity.
Conclusions
Several reports suggest that some of the tumor suppressor functions of PTEN are mediated independently of its ability to breakdown PtdIns(3,4,5)P 3 , for example, by dephosphorylating other substrates (reviewed in [3, 4] ) or through the ability of its C2 domain to control cell migration [24] . Moreover, elevated levels of PtdIns(3,4,5)P 3 resulting from a loss of PTEN, will activate several signaling processes in addition to PDK1-PKB-S6K pathway [1, 2] . The importance of these other networks in mediating the tumor suppressor activity of PTEN is unknown, but the results described in this study provides strong genetic evidence that PDK1 is a key effector in mediating tumorigenesis resulting from loss of PTEN. Our findings also support the notion that PDK1 is an attractive target for the development of drugs to prevent cancers that possess elevated PtdIns(3,4,5)P 3 levels and/or possess increased PKB and S6K activity. Further work will be required to establish the mechanism by which reduction in PDK1 levels markedly inhibits the onset of tumor formation and whether this involves decreased activation of PKB/S6K and/or other PDK1 targets.
Experimental Procedures
Materials
Taq DNA polymerase was purchased from Promega. Protein G-Sepharose and Streptavidin-Sepharose High Performance were purchased from Amersham Pharmacia Biotech. Roche supplied protease inhibitor cocktail tablets.
Antibodies
The PDK1 antibody used for immunoblotting and activity was raised in sheep against the sequence RKIQEVWRQQYQSNP DAAVQ (residues 540-559 of mouse PDK1). The ERK2 antibody was raised in sheep against the full-length human protein. Both antibodies were affinity purified with the appropriate antigen. The PTEN monoclonal antibody raised against amino acids 388-400 mapping at the C terminus of human PTEN was purchased from Santa Cruz Biotechnology (sc-7944). Monoclonal glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was purchased from Chemicon (#SC5 clone). Secondary antibodies coupled to horseradish peroxidase were from Pierce. , lost over 20% in body weight, or showed signs of sickness was culled and subjected to necropsy and pathological analysis after fixation of tissues in 10% formalin as described below.
Mice Breeding and Genotype Analysis
Analysis of Tumors
After 15 months of age, surviving mice were culled, necropsy was performed, and all tissues were immediately fixed in 10% buffered formalin (Pre-filled Biopsy Pots, BIOS Europe, #BP120BF) and subsequently embedded in paraffin. 5 m thick sections were cut, deparaffinized, and stained with haematoxylin and eosin for histological analysis employing standard protocols. Sections were viewed on a Nikon Eclipse 600 microscope and images captured on a Nikon DXM1200 digital camera supported by EclipseNet software.
Assay of PDK1 and PTEN PDK1 was immunoblotted and assayed after its immunoprecipitation from tissue extracts employing the PDKtide peptide as described previously [15] . PTEN activity was measured following its immunoprecipitation from tissue extracts employing 33 P-labeled PtdIns(3,4,5)P 3 as described previously [25] .
Immunohistochemistry Analysis
Tumor slices were generated as described above and subjected to heat-induced antigen retrieval. Immunohistochemical staining was performed with automated procedures at the Surgery and Molecular Oncology Department of the Ninewells hospital. The FOXO1 antibody (Cell Signaling #9462) was used at a dilution of 1/160, the Phospho-S6 Ser235/236 antibody (Cell Signaling #4857) used at a dilution of1/400 and the Ki67 antibody employed (VectorLabs clone SP6) at a dilution of 1/200. Antibody staining was detected using the rabbit Vectastain ABC Kit (VectorLabs).
Statistical Analysis
The chi-square test and the Fisher's Exact Test were performed to compare the incidence of the different types of tumors in the two genotypes analyzed, whereas the Student's t test was used to compare weights and activities measurements. 
